Second-line systemic therapy for metastatic urothelial carcinoma of the bladder
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Second-line systemic therapy for metastatic urothelial carcinoma of the bladder
Authors
Keywords
-
Journal
Future Oncology
Volume 9, Issue 11, Pages 1637-1651
Publisher
Future Medicine Ltd
Online
2013-10-24
DOI
10.2217/fon.13.139
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy
- (2013) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum–gemcitabine regimen
- (2012) Julien Edeline et al. EUROPEAN JOURNAL OF CANCER
- Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials
- (2012) Guru Sonpavde et al. EUROPEAN UROLOGY
- Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma
- (2012) Yu-Ning Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
- (2012) Andrea Necchi et al. LANCET ONCOLOGY
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Sunitinib Malate Provides Activity Against Murine Bladder Tumor Growth and Invasion in a Preclinical Orthotopic Model
- (2012) Eddie Shu-yin Chan et al. UROLOGY
- Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls
- (2011) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: A phase II study of the SUOC group
- (2011) Hiroshi Kitamura et al. CANCER SCIENCE
- Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-Based Chemotherapy
- (2011) Matthew D. Galsky et al. Clinical Genitourinary Cancer
- Prognostic Factors in Second-Line Treatment of Urothelial Cancers With Gemcitabine and Paclitaxel (German Association of Urological Oncology Trial AB20/99)
- (2011) Günter Niegisch et al. EUROPEAN UROLOGY
- Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens
- (2011) Jae Young Joung et al. INTERNATIONAL JOURNAL OF UROLOGY
- Combination of Gemcitabine and Paclitaxel is a Favorable Option for Patients with Advanced or Metastatic Urothelial Carcinoma Previously Treated with Cisplatin-based Chemotherapy
- (2011) M. Ikeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]
- (2010) P. Albers et al. ANNALS OF ONCOLOGY
- Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder
- (2010) Christian Bolenz et al. BJU INTERNATIONAL
- Bladder cancer: translating molecular genetic insights into clinical practice
- (2010) Liang Cheng et al. HUMAN PATHOLOGY
- Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer
- (2010) David J. Gallagher et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
- (2010) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
- (2010) Guru Sonpavde et al. LANCET ONCOLOGY
- Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study
- (2010) Antonio Rozzi et al. MEDICAL ONCOLOGY
- Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
- (2010) Przemyslaw Twardowski et al. UROLOGY
- Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
- (2009) M. Lae et al. ANNALS OF ONCOLOGY
- Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma
- (2009) William E. Osai et al. ANTI-CANCER DRUGS
- Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium
- (2009) Daniel P. Petrylak et al. BJU INTERNATIONAL
- Phase 2 trial of sorafenib in patients with advanced urothelial cancer
- (2009) Robert Dreicer et al. CANCER
- A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
- (2009) Christian Wülfing et al. CANCER
- Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma
- (2009) David J. Vaughn et al. CANCER
- A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma
- (2009) Sandy Srinivas et al. CHEMOTHERAPY
- Arsenic Trioxide in Recurrent Urothelial Cancer: A Cancer and Leukemia Group B Phase II Trial (CALGB 99903)
- (2009) Dean F. Bajorin et al. Clinical Genitourinary Cancer
- Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study
- (2009) Florence Joly et al. Clinical Genitourinary Cancer
- A Phase II Trial of Continuous 5-Fluorouracil in Recurrent or Metastatic Transitional Cell Carcinoma of the Urinary Tract
- (2009) M.S. Highley et al. CLINICAL ONCOLOGY
- Combination of Gemcitabine and Paclitaxel as Second-line Chemotherapy for Advanced Urothelial Carcinoma
- (2009) T. Suyama et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
- (2008) J. E. Rosenberg et al. ANNALS OF ONCOLOGY
- Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells
- (2008) P. C. Black et al. CLINICAL CANCER RESEARCH
- Vinflunine: A New Microtubule Inhibitor Agent
- (2008) J. Bennouna et al. CLINICAL CANCER RESEARCH
- Southwest Oncology Group Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium that Progressed After Platinum-Based Chemotherapy
- (2008) Tomasz M. Beer et al. Clinical Genitourinary Cancer
- Phase II Open-Label Study of Oral Piritrexim in Patients with Advanced Carcinoma of the Urothelium Who Have Experienced Failure with Standard Chemotherapy
- (2008) Lance K. Lassiter et al. Clinical Genitourinary Cancer
- Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy
- (2008) Kunimitsu Kanai et al. International Journal of Clinical Oncology
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- (2008) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity of Vinflunine: Effector Pathways and Potential for Synergies
- (2008) Diane Braguer et al. SEMINARS IN ONCOLOGY
- Potential Mechanisms of Resistance to Microtubule Inhibitors
- (2008) Maria Kavallaris et al. SEMINARS IN ONCOLOGY
- Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
- (2008) Guru Sonpavde et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now